Coreline Soft Co., Ltd.
KKRX:3844702,295.00
KRW
-45.00
(-1.92%)
ISIN
KR7384470001
Return %
Stock
S&P 500
1Y
-46.13
14.39
3Y
-85.07
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jin-Guk Kim
- Full Time Employees
- 99
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Seoul South Korea
- IPO Date
- Sep 18, 2023
- Website
- corelinesoft.com
- Similar Companies
- Business
- Coreline Soft Co., Ltd. is a South Korea-based medical artificial intelligence (AI) software company specializing in the development and commercialization of deep learning-powered medical imaging diagnostic and computer-aided detection solutions, primarily focused on thoracic and cardiopulmonary computed tomography (CT) analysis. Founded in 2012 and headquartered in Seoul, South Korea, the company operates within the healthcare technology and medical software industries, serving hospitals, specialized imaging clinics, academic research institutions, and government-sponsored national health screening programs worldwide. The company provides a comprehensive suite of cloud-ready and on-premise AI imaging solutions under its proprietary AVIEW brand, which includes: AVIEW LCS, an AI-based low-dose chest CT screening solution for lung cancer detection, pulmonary nodule segmentation, and longitudinal tracking; AVIEW LCS Plus, a simultaneous multi-disease screening platform designed to detect lung cancer, chronic obstructive pulmonary disease (COPD), and coronary artery calcification from a single non-contrast chest CT scan; AVIEW CAC, an automated coronary artery calcium scoring and cardiovascular risk stratification system; AVIEW COPD, a quantitative analysis application measuring emphysema index, lung volume distribution, and airway wall morphology; AVIEW Aorta, an automated vascular diagnostic tool for detecting and measuring aortic aneurysms and acute aortic syndrome; AVIEW Lung Texture, an imaging biomarker application for interstitial lung disease evaluation; AVIEW NeuroCAD, an emergency neurovascular triage solution for rapid intracranial hemorrhage detection on non-contrast head CT; AVIEW RT ACS, an automated organ-at-risk segmentation and contouring software for radiation oncology treatment planning; and AVIEW Modeler, a 3D medical image processing platform for surgical planning and medical 3D printing. In recent developments, Coreline Soft completed its public listing on the KOSDAQ market (KRX: 384470) following a merger with Shinhan No. 7 Special Purpose Acquisition Company (SPAC). The company has accelerated its international commercial expansion through its overseas subsidiaries, including Coreline Soft Europe GmbH in Germany and Coreline Soft USA Inc., and has established strategic commercial partnerships and marketplace integrations with global healthcare technology platforms such as Bayer, Blackford Analysis, TeraRecon, and Nuance Communications. Coreline Soft has expanded its footprint in high-profile multinational lung cancer screening initiatives, securing major commercial implementations across the European Union, the United Kingdom, and the Asia-Pacific region, while securing multiple U.S. FDA 510(k) clearances and European CE (MDR) certifications across its expanding emergency triage and thoracic portfolio.